Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients

被引:33
作者
Fruendt, Thorben [1 ]
Krause, Linda [2 ]
Hussey, Elaine [1 ]
Steinbach, Bettina [3 ]
Koehler, Daniel [4 ]
von Felden, Johann [1 ]
Schulze, Kornelius [1 ]
Lohse, Ansgar W. [1 ]
Wege, Henning [1 ,5 ]
Schwarzenbach, Heidi [3 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, D-20246 Hamburg, Germany
[2] Inst Med Biometry & Epidemiol, D-20246 Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, D-20246 Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Dept Diagnost & Intervent Radiol & Nucl Med, D-20246 Hamburg, Germany
[5] Canc Ctr Esslingen, D-73730 Esslingen, Germany
关键词
microRNAs; exosomes; hepatocellular carcinoma; liver cirrhosis; survival prediction; BREAST-CANCER PATIENTS; CELL-FREE MICRORNAS; NEOADJUVANT THERAPY; NATURAL-HISTORY; SERUM-LEVELS; SORAFENIB; METASTASIS; MIR-373; COHORT;
D O I
10.3390/cancers13102484
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Exosomes, carrying small non-coding RNA (miRNA), are known to play a pivotal role in the process of tumor progression. In this prospective study, we identified miR-16, miR-146a, miR-192, and miR- 221 to be significantly deregulated in the plasma of patients with hepatocellular carcinoma (HCC) compared to patients with liver cirrhosis and healthy individuals. MiR-146a revealed diagnostic potential to differentiate HCC patients from liver cirrhosis patients with a sensitivity of 81% and a specificity of 58% in logistic regression model. Furthermore, miR- 192 independently correlated with overall survival in patients with HCC. We aimed to identify a specific microRNA (miRNA) pattern to determine diagnostic and prognostic value in plasma exosomes of hepatocellular carcinoma (HCC) patients. A two-stage study was carried out: exosomal miRNAs were quantified in plasma of HCC patients and healthy individuals by PCR-based microarray cards containing 45 different miRNAs (training cohort). Then, four deregulated miRNAs (miR-16, miR-146a, miR-192, and miR-221) were quantified in the validation analysis using exosomes derived from 85 HCC patients, 50 liver cirrhosis patients, and 20 healthy individuals. Exosomal miR-146a (p = 0.0001), miR-192 (p = 0.002) and miR-221 (p = 0.032) were upregulated only in HCC patients. Repeated 10-fold cross validation showed that miR-146a differentiated HCC from liver cirrhosis patients with AUC of 0.80 +/- 0.14 (sensitivity: 81 +/- 13%, specificity: 58 +/- 22%) in a logistic regression model. High miR-192 presence is associated with poor overall survival (OS) in all HCC patients (p = 0.027) and was predictor of OS in HCC patients in an uni- and multivariate Cox regression model. Moreover, decreased miR-16 levels correlated with OS in liver cirrhosis patients (p = 0.034). Our results emphasized that exosomes secreted into the plasma carry differentially expressed miRNAs of which in particular, miR-192, miR-146, and miR-16 are promising diagnostic and prognostic markers for both HCC and liver cirrhosis patients.
引用
收藏
页数:17
相关论文
共 48 条
  • [11] RETRACTED: AEG-1/miR-221 Axis Cooperatively Regulates the Progression of Hepatocellular Carcinoma by Targeting PTEN/PI3K/AKT Signaling Pathway (Retracted article. See vol. 23, 2022)
    Kannan, Maheshkumar
    Jayamohan, Sridharan
    Moorthy, Rajesh Kannan
    Chabattula, Siva Chander
    Ganeshan, Mathan
    Arockiam, Antony Joseph Velanganni
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (22)
  • [12] miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway
    Kim, Jihye
    Jiang, Jinmai
    Badawi, Mohamed
    Schmittgen, Thomas D.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 487 (03) : 709 - 715
  • [13] Gα12 overexpression induced by miR-16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells
    Kim, Kyu Min
    Han, Chang Yeob
    Kim, Ji Young
    Cho, Sam Seok
    Kim, Yun Seok
    Koo, Ja Hyun
    Lee, Jung Min
    Lim, Sung Chul
    Kang, Keon Wook
    Kim, Jae-Sung
    Hwang, Se Jin
    Ki, Sung Hwan
    Kim, Sang Geon
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 (03) : 493 - 504
  • [14] Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma
    Kim, Soon Sun
    Nam, Ji Sun
    Cho, Hyo Jung
    Won, Je Hwan
    Kim, Jin Woo
    Ji, Jae-Hoon
    Yang, Min Jae
    Park, Joo Han
    Noh, Choong-Kyun
    Shin, Sung Jae
    Lee, Kee Myung
    Cho, Sung Won
    Cheong, Jae Youn
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (01) : 199 - 207
  • [15] Haemolysis during Sample Preparation Alters microRNA Content of Plasma
    Kirschner, Michaela B.
    Kao, Steven C.
    Edelman, J. James
    Armstrong, Nicola J.
    Vallely, Michael P.
    van Zandwijk, Nico
    Reid, Glen
    [J]. PLOS ONE, 2011, 6 (09):
  • [16] Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: Experience from a German referral center
    Kirstein, Martha M.
    Schweitzer, Nora
    Winter, Theresa
    Lappas, Katerina
    Graen, Nathalie
    Kunstmann, Isabell
    Voigtlaender, Torsten
    Reineke-Plaass, Tanja
    Manns, Michael P.
    Lehner, Frank
    Rodt, Thomas
    Vogel, Arndt
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (10) : 1730 - 1738
  • [17] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    [J]. LANCET, 2018, 391 (10126) : 1163 - 1173
  • [18] Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort study of 257 patients in Toronto
    Levy, I
    Sherman, M
    [J]. GUT, 2002, 50 (06) : 881 - 885
  • [19] Prognosis of hepatocellular carcinoma:: The BCLC staging classification
    Llovet, JM
    Brú, C
    Bruix, J
    [J]. SEMINARS IN LIVER DISEASE, 1999, 19 (03) : 329 - 338
  • [20] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390